Anavex Life Sciences Corp (AVXL)

[Biostockclub]

Re MS indication:

Turns out pharmaceutical licensing does fall under the Clayton Anti-trust legislation and the HSR (Hart-Scott-Rodino) Act - amended in 2013 per below.

IF a deal is being reviewed by the FTC/DOJ between Anavex and Biogen for any portion of the recently approved IP, the protection we were waiting for, although that deal would be incredibly material to company shareholders (both companies), it is 100% non-disclosable during the review period. Not even subject to a FOIA request.

https://www.federalregister.gov/documents/2013/11/15/2013-27027/premerger-notification-reporting-and-waiting-period-requirements

Very long read, but with the advent of IP and licensing agreements/deals in pharma industry only (emphasis), this was addressed as a special case and was amended and spelled out very clearly.

Bottom line: MS MTA could have been pitched and Anavex decided to never mention any outcome and just "disappear" any/every mention from its presentations and website.
Or, a deal has been negotiated and is under review by regulatory bodies, in which case neither entity can say anything - until it is okayed - then announcement could come at a moment's notice - PR, would not have to be at a scheduled conference of any type. In fact, if deal were made and approved, then it would become material and disclosable and would be subject to a prompt, timely, disclosure which rulings have been discussed in the posts.

The regulations are factual. The options are clear. Take your pick. I'm presenting facts, not endorsing or speculating.